GlaxoSmithKline: Renal Insufficiency, Chronic trials
The registry lists 16 Renal Insufficiency, Chronic studies with GlaxoSmithKline as lead sponsor. 0 are open to participants now and 16 have results posted.
Phase 1 1Phase 2 8Phase 3 7(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P)CompletedNCT05682326Phase 3Results posted
- Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)CompletedNCT03457701Phase 2Results posted
- Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)CompletedNCT03409107Phase 3Results posted
- Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)CompletedNCT03029208Phase 3Results posted
- A Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)CompletedNCT02969655Phase 3Results posted
- Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)CompletedNCT02879305Phase 3Results posted
- Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)CompletedNCT02876835Phase 3Results posted
- Phase III Study of GSK1278863 in Japanese Non-dialysis (ND) and Peritoneal Dialysis (PD) Subjects With Renal AnemiaCompletedNCT02791763Phase 3Results posted
- Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating AgentCompletedNCT02689206Phase 2Results posted
- Study to Assess the Pharmacokinetics of GSK1278863 in Subjects With End Stage Renal Disease Undergoing Peritoneal DialysisCompletedNCT02243306Phase 1Results posted
- Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoietin (rhEPO) Hyporesponsive Hemodialysis-dependent Chronic Kidney Disease Subjects With AnemiaTerminatedNCT02075463Phase 2Results posted
- Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Japanese Hemodialysis-Dependent Subjects With Anemia Associated With Chronic Kidney DiseaseCompletedNCT02019719Phase 2Results posted
- A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)CompletedNCT01977573Phase 2Results posted
- Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated AnemiaCompletedNCT01977482Phase 2Results posted
- 4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney DiseaseCompletedNCT01587924Phase 2Results posted
- 4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing DialysisCompletedNCT01587898Phase 2Results posted